Therapeutic Solutions International is a regenerative medicine and immunotherapy company which was trading around 0.002 per share when Dr.Ichim came on board, initially as consultant, and subsequently as board member. Dr. Ichim secured funding, obtained numerous patents and regulatory clearances, as well as attracted internationally recognized collaborators and advisory board members. As a result the Company experienced over 10000% appreciation in share price, as well as numerous financings.
Dr. Reznik met the CEO of Cytovia Therapeutics in 2020, the two quickly partnered to help the company realize its incredible potential. After we helped the company move its headquarters to Miami in 2021, our participation has increased significantly. Multiple rounds of private financing, helping in negotiation and execution of ISLE SPAC M&A ($369M) agreement, and connecting the company to an investment banker, while working on an IPO. It has been a rewarding journey that is continues to develop.
Medistem (MEDS) Medistem, a company that specializes in the development of technologies pertaining to adult stem cells, faced a considerable decline in the value of its shares, plummeting to a mere 7 cents per share. The company sought to improve its situation by naming Dr. Ichim as the CEO. With our active participation, the company was able to obtain Investigational New Drug approval from the FDA for the initial human use of endometrial stem cells. Under Dr. Ichims’ leadership, Medistem successfully established a robust portfolio of potential candidates, attracted experienced management, and ultimately sold the company to a NYSE traded entity, Intrexon, for $1.35 per share.
Hospira, Inc. (M&A $14.5B) In 2013, Hospira was experiencing difficulties as their stock price remained stagnant at approximately $30. It was during this time that Dr. Reznik had an interaction with their Senior Vice President, which led us to assist with their recently established strategic plan of creating biosimilars. Our contribution eventually resulted in the approval of Hospira’s initial biosimilar and the company’s acquisition by Pfizer at $90 per share in 2016. During a Hospira board meeting, the Senior Vice President credited our thorough engagement for the remarkable 300% appreciation in valuation.
Medistem (MEDS) Medistem, a company that specializes in the development of technologies pertaining to adult stem cells, faced a considerable decline in the value of its shares, plummeting to a mere 7 cents per share. The company sought to improve its situation by naming Dr. Ichim as the CEO. With our active participation, the company was able to obtain Investigational New Drug approval from the FDA for the initial human use of endometrial stem cells. Under Dr. Ichims’ leadership, Medistem successfully established a robust portfolio of potential candidates, attracted experienced management, and ultimately sold the company to a NYSE traded entity, Intrexon, for $1.35 per share.
Hospira, Inc. (M&A $14.5B) In 2013, Hospira was experiencing difficulties as their stock price remained stagnant at approximately $30. It was during this time that Dr. Reznik had an interaction with their Senior Vice President, which led us to assist with their recently established strategic plan of creating biosimilars. Our contribution eventually resulted in the approval of Hospira’s initial biosimilar and the company’s acquisition by Pfizer at $90 per share in 2016. During a Hospira board meeting, the Senior Vice President credited our thorough engagement for the remarkable 300% appreciation in valuation.
Regen BioPharma (RGBP) Regen BioPharma is an oncology and cell therapy company in which Dr. Ichim identified various intellectual property assets that served as the basis for founding the company as a private subsidiary of a public company. Dr. Ichim positioned the company through leading development of preclinical assets to FDA clearance and successful clinical trials. The company, which was subsequently spun off as an independent entity, had a price appreciation of over 5000%.
Apellis Pharmaceuticals (APLS) IPO $689M to $9.1B Dr. Reznik met the CEO of Apellis in 2017, after the company had their IPO, which valued at $689M. We have been working with Apellis on several of their important programs, contributing to incredible successes, leading to corresponding increases in its valuation. We are proud of our substantial contribution which has attained Apellis’ current valuation of $9.1B.
